ethyltriphenylphosphonium bromide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyltriphenylphosphonium bromide
• 英文别名: bromo(ethyl)triphenylphosphorane；Bromo-ethyl-triphenyl-lambda5-phosphane；bromo-ethyl-triphenyl-λ5-phosphane
• 化学式: C₂₀H₂₀BrP
• 分子量: 371.257
• InChiKey: RZWDOHOQSSGFOR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  ethyltriphenylphosphonium bromide 在 正丁基锂 作用下， 以 乙醚 、 正己烷 为溶剂， 生成 亚乙基(三苯基)-lambda~5~-磷烷
  参考文献：
  名称：

  Synthesen endständig substituierter, konjugierter Polyene

  摘要：

  端取代共轭多烯的合成类胡萝卜素型多烯和多烯醛具有五个、九个和十三个共轭双键以及各种端取代基，如苯、萘、蒽和四苯基卟啉，可分别从鳄梨甙二醛或 2,7 二甲基辛二烯醛开始，通过威蒂希反应合成。这些多烯的 E/Z 异构体可以进行表征，在大多数情况下还可以进行分离。

  DOI：

  10.1055/s-1990-27102
• 作为产物：
  描述：

  [1-(Ethoxycarbonyl)ethyl]triphenylphosphoniumbromide 以61%的产率得到
  参考文献：
  名称：

  DING, WEI-YU;CAI, WEN;PU, JIA-QI;SHEN, WEI-PING;DAI, JIN-SHAN, ACTA CHIM. SIN., 1985, 43, N 1, 53-56

  摘要：

  DOI：
• 作为试剂：
  描述：

  甲基溴化镁 、 4-溴-N-甲氧基-N,2-二甲基苯甲酰胺 在 ethyltriphenylphosphonium bromide 、 sodium hexamethyldisilazane 作用下， 生成 4-Bromo-2-methyl-1-prop-1-en-2-ylbenzene
  参考文献：
  名称：

  Synthesis and SAR of 1,3-thiazolyl thiophene and pyridine derivatives as potent, orally active and S1P3-sparing S1P1 agonists

  摘要：

  We have previously disclosed 1,2,4-oxadiazole derivative 3 as a potent S1P(3)-sparing S1P(1) agonist. Although compound 3 exhibits potent and manageable immunosuppressive efficacy in various in vivo models, recent studies have revealed that its 1,2,4-oxadiazole ring is subjected to enterobacterial decomposition. As provisions for unpredictable issues, a series of alternative compounds were synthesized on the basis of compound 3. Extensive SAR studies led to the finding of 1,3-thiazole 24c with the EC50 value of 3.4 nM for human S1P(1), and over 5800-fold selectivity against S1P(3). In rat on host versus graft reaction (HvGR), the ID50 value of 24c was determined at 0.07 mg/kg. The pharmacokinetics in rat and monkey is also reported. Compared to compound 3, 24c showed excellent stability against enterobacteria. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.067

文献信息

• Pd-^<i>t</i> BuONO Cocatalyzed Aerobic Indole Synthesis
  作者：Xiao-Shan Ning、Xin Liang、Kang-Fei Hu、Chuan-Zhi Yao、Jian-Ping Qu、Yan-Biao Kang

  DOI：10.1002/adsc.201701512

  日期：2018.4.17

  A Pd‐tBuONO co‐catalyzed scalable and practical synthesis of indoles with molecular oxygen as terminal oxidant is developed. Either terminal or internal 2‐vinylanilines could be smoothly converted to desired indoles under one general condition. This method has been evaluated in the large scale synthesis of indomethacin and a potential anti‐breast cancer drug candidate 1.

  甲的Pd-吨作为终端氧化剂被显影BUONO共催化的分子氧吲哚的可扩展性和实用的合成。在一种通用条件下，末端或内部2乙烯基苯胺均可顺利转化为所需的吲哚。吲哚美辛和潜在的抗乳腺癌候选药物1的大规模合成已对该方法进行了评估。
• ANTIVIRAL COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20140178336A1

  公开（公告）日：2014-06-26

  The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  该披露涉及抗病毒化合物，含有这种化合物的组合物，包括给予这种化合物的治疗方法，以及用于制备这种化合物的有用过程和中间体。
• [EN] OXYSTEROLS AND METHODS OF USE THEREOF<br/>[FR] OXYSTÉROLS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SAGE THERAPEUTICS INC

  公开号：WO2018075698A1

  公开（公告）日：2018-04-26

  Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

  根据公式(A)提供化合物：以及药用可接受的盐和药物组合物；其中R1、R2、R3、R4、R5、R6和RG如本文所述定义。本发明的化合物被认为对预防和治疗多种疾病有用。
• Intramolecular Anodic Olefin Coupling Reactions and the Synthesis of Cyclic Amines
  作者：Hai-Chao Xu、Kevin D. Moeller

  DOI：10.1021/ja910586v

  日期：2010.3.3

  Anodic olefin coupling reactions using a tosylamine trapping group have been studied. The cyclizations are favored by the use of a less-polar radical cation and more basic reaction conditions. The most significant factor for obtaining good yields of cyclic product is the use of the more basic reaction conditions. However, a number of factors including the nature of both the solvent and the electrolyte

  已经研究了使用甲苯磺胺捕获基团的阳极烯烃偶联反应。使用极性较小的自由基阳离子和碱性更强的反应条件有利于环化。获得良好的环状产物收率的最重要因素是使用更碱性的反应条件。然而，包括所用溶剂和电解质的性质在内的许多因素会影响环化的产率。环化允许快速合成取代的脯氨酸和哌啶酸类型的衍生物。
• [EN] 1,2,3,4-TETRAHYDROISOQUINOLINE COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR ANTAGONISTS AND DEGRADERS<br/>[FR] COMPOSÉS ET COMPOSITIONS DE 1,2,3,4-TÉTRAHYDROISOQUINOLÉINE EN TANT QU'ANTAGONISTES ET AGENTS DE DÉGRADATION SÉLECTIFS DES RÉCEPTEURS DES ŒSTROGÈNES
  申请人：NOVARTIS AG

  公开号：WO2015092634A1

  公开（公告）日：2015-06-25

  The present invention relates to compounds of formula (I) in which n, R1, R2, R3, R4and R5 are as defined in the claims; capable of being both potent antagonists and degraders of estrogen receptors. Also described is a process for the preparation of compounds of the invention, and the invention further provides pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.

  本发明涉及式(I)化合物，其中n、R1、R2、R3、R4和R5如权利要求所述；能够作为雌激素受体的强效拮抗剂和降解剂。还描述了制备本发明化合物的方法，并且本发明进一步提供了包含该化合物的药物制剂以及使用该化合物和组合物管理与异常雌激素受体活性相关疾病或失调的方法。